Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
3.250
-0.140 (-4.13%)
At close: Dec 5, 2025, 4:00 PM EST
3.310
+0.060 (1.85%)
After-hours: Dec 5, 2025, 5:14 PM EST
Camp4 Therapeutics Employees
Camp4 Therapeutics had 55 employees as of December 31, 2024. The number of employees decreased by 9 or -14.06% compared to the previous year.
Employees
55
Change (1Y)
-9
Growth (1Y)
-14.06%
Revenue / Employee
$69,127
Profits / Employee
-$970,873
Market Cap
152.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | -9 | -14.06% |
| Dec 31, 2023 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CAMP News
- 22 days ago - CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 2 months ago - CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewsWire
- 3 months ago - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders - GlobeNewsWire
- 4 months ago - CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 7 months ago - CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 7 months ago - CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 7 months ago - CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire